Ligand Pharmaceuticals Inc
LGND133.654USD
+0.934+0.70%
Horário de mercado （ET）Cotações atrasadas em 15 min
2.58BValor de mercado
PerdaP/L TTM
Mais detalhes de Ligand Pharmaceuticals Inc Empresa
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Informações da empresa
Código da empresaLGND
Nome da EmpresaLigand Pharmaceuticals Inc
Data de listagemNov 18, 1992
CEOMr. Todd C. Davis
Número de funcionários68
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 18
Endereço555 Heritage Drive, Suite 200
CidadeJUPITER
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal33458
Telefone18585507500
Sitehttps://www.ligand.com/
Código da empresaLGND
Data de listagemNov 18, 1992
CEOMr. Todd C. Davis
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
137.16K
+0.89%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
45.30K
-2.02%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
17.05K
-4.31%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
9.35K
+14.86%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.86K
+21.40%
Dr. Martine Zimmermann, Pharm.D.
Dr. Martine Zimmermann, Pharm.D.
Independent Director
Independent Director
4.29K
+31.26%
Mr. Todd C. Davis
Mr. Todd C. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
137.16K
+0.89%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
45.30K
-2.02%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
17.05K
-4.31%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Captisol
13.46M
29.69%
Qarziba
5.44M
12.00%
Filspari
5.30M
11.69%
Kyprolis
4.72M
10.42%
Milestone
4.38M
9.67%
Other
12.02M
26.52%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Captisol
13.46M
29.69%
Qarziba
5.44M
12.00%
Filspari
5.30M
11.69%
Kyprolis
4.72M
10.42%
Milestone
4.38M
9.67%
Other
12.02M
26.52%
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
13.86%
The Vanguard Group, Inc.
10.63%
Janus Henderson Investors
5.33%
Macquarie Investment Management
4.70%
Dimensional Fund Advisors, L.P.
3.86%
Other
61.62%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
13.86%
The Vanguard Group, Inc.
10.63%
Janus Henderson Investors
5.33%
Macquarie Investment Management
4.70%
Dimensional Fund Advisors, L.P.
3.86%
Other
61.62%
Tipos de investidores
Investidores
Proporção
Investment Advisor
57.94%
Investment Advisor/Hedge Fund
37.89%
Individual Investor
2.39%
Research Firm
1.84%
Pension Fund
1.60%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.28%
Hedge Fund
0.05%
Insurance Company
0.03%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
534
19.71M
102.14%
-793.05K
2025Q1
554
19.82M
102.82%
-711.89K
2024Q4
546
19.28M
100.16%
-1.51M
2024Q3
543
19.17M
104.83%
-583.22K
2024Q2
527
18.31M
101.74%
-865.78K
2024Q1
520
17.60M
99.35%
-393.03K
2023Q4
527
16.97M
97.29%
-861.76K
2023Q3
515
17.24M
99.38%
-910.17K
2023Q2
526
17.09M
98.94%
-1.02M
2023Q1
528
16.47M
96.50%
-1.33M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
2.67M
13.86%
-26.33K
-0.97%
Mar 31, 2025
The Vanguard Group, Inc.
2.05M
10.63%
-29.89K
-1.44%
Mar 31, 2025
Janus Henderson Investors
1.03M
5.33%
+12.53K
+1.23%
Mar 31, 2025
Macquarie Investment Management
906.23K
4.7%
+21.85K
+2.47%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
744.93K
3.86%
+21.91K
+3.03%
Mar 31, 2025
State Street Global Advisors (US)
727.13K
3.77%
-16.51K
-2.22%
Mar 31, 2025
Congress Asset Management Company, LLP
642.71K
3.33%
+21.23K
+3.42%
Mar 31, 2025
Stephens Investment Management Group, LLC
607.22K
3.15%
-5.56K
-0.91%
Mar 31, 2025
Chicago Capital, LLC
554.52K
2.87%
+2.93K
+0.53%
Mar 31, 2025
Geode Capital Management, L.L.C.
464.45K
2.41%
+26.01K
+5.93%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Invesco Pharmaceuticals ETF
3.03%
Virtus LifeSci Biotech Products ETF
1.91%
SPDR S&P Pharmaceuticals ETF
1.86%
Franklin Genomic Advancements ETF
1.68%
Invesco S&P SmallCap Health Care ETF
1.57%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.34%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.32%
iShares U.S. Pharmaceuticals ETF
1.1%
First Trust Multi-Manager Small Cap Opportunities ETF
0.71%
Simplify Health Care ETF
0.52%
Ver Mais
Invesco Pharmaceuticals ETF
Proporção3.03%
Virtus LifeSci Biotech Products ETF
Proporção1.91%
SPDR S&P Pharmaceuticals ETF
Proporção1.86%
Franklin Genomic Advancements ETF
Proporção1.68%
Invesco S&P SmallCap Health Care ETF
Proporção1.57%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporção1.34%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.32%
iShares U.S. Pharmaceuticals ETF
Proporção1.1%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporção0.71%
Simplify Health Care ETF
Proporção0.52%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
